7. Predictive values of the index tests and prevalences.

Predictive values of the index tests and prostate cancer prevalences
Test	MRI populationa	Target condition	N participants (studies)	Prevalenceb (95% CI)	NPVc (95% CI)	PPVc (95% CI)
MRI	Positive + negative	G = 1	1764 (10)	0.20 (0.17 to 0.23)	0.79 (0.74 to 0.82)	0.20 (0.18 to 0.21)
		G ≥ 2	3091 (12)	0.29 (0.22 to 0.38)	0.91 (0.86 to 0.94)	0.37 (0.35 to 0.39)
		G ≥ 3	1438 (7)	0.14 (0.08 to 0.23)	0.98 (0.95 to 0.99)	0.19 (0.17 to 0.21)
MRI‐TBx	Positive	G = 1	497 (5)	0.22 (0.19 to 0.26)	0.88 (0.78 to 0.94)	0.98 (0.23 to 1.00)
		G ≥ 2	1553 (8)	0.34 (0.24 to 0.46)	0.90 (0.85 to 0.93)	0.88 (0.80 to 0.92)
		G ≥ 3	428 (3)	0.21 (0.12 to 0.35)	ID	ID
MRI‐pathway	Positive + negative	G = 1	681 (5)	0.21 (0.18 to 0.24)	0.85 (0.81 to 0.88)	0.95 (0.38 to 1.00)
		G ≥ 2	2257 (8)	0.26 (0.18 to 0.36)	0.91 (0.87 to 0.94)	0.88 (0.80 to 0.92)
		G ≥ 3	604 (3)	0.16 (0.09 to 0.27)	ID	ID
SBx	NA	G = 1	3421 (4)	0.20 (0.16 to 0.25)	0.90 (0.81 to 0.95)	0.94 (0.37 to 1.00)
		G ≥ 2	3421 (4)	0.34 (0.21 to 0.51)	0.84 (0.60 to 0.95)	1.00 (0.76 to 1.00)
		G ≥ 3	626 (2)	0.10 (0.08 to 0.12)	ID	ID
CI: confidence interval; G: International Society of Urological Pathology grade; ID: inadequate data; MRI: magnetic resonance imaging; MRI‐pathway: magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; MRI‐TBx: magnetic resonance imaging‐targeted biopsy; NA: not applicable; NPV: negative predictive value; PPV: positive predictive value; SBx: systematic biopsy

^aData did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men).
 ^bPrevalence is pooled estimate of all detected cancer by template‐guided biopsy.
 ^cBased on the Bayes’ theorem using the point estimates and 95% confidence intervals of the pooled positive and negative likelihood ratio and the point estimate of the prevalence.